RSCM
CLDX icon

Rock Springs Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Rock Springs Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26M Buy
699,146
+48,876
+8% +$1.58M 1.27% 20
2026
Q1 		$20.6M Sell
650,270
-42,268
-6% -$1.15M 1.22% 25
2025
Q4 		$18.8M Sell
692,538
-29,000
-4% -$764K 0.96% 33
2025
Q3 		$18.7M Sell
721,538
-91,115
-11% -$2.11M 1.09% 31
2025
Q2 		$16.5M Hold
812,653
– – 1.03% 32
2025
Q1 		$14.7M Sell
812,653
-409,529
-34% -$9.15M 0.84% 44
2024
Q4 		$30.9M Buy
1,222,182
+118,404
+11% +$3.22M 1.18% 31
2024
Q3 		$37.5M Sell
1,103,778
-295,216
-21% -$11.2M 1.22% 33
2024
Q2 		$51.8M Buy
1,398,994
+26,809
+2% +$1.01M 1.56% 22
2024
Q1 		$57.6M Buy
1,372,185
+402,539
+42% +$16.5M 1.46% 22
2023
Q4 		$38.5M Buy
969,646
+469,545
+94% +$13.8M 0.95% 37
2023
Q3 		$13.8M Buy
500,101
+78,486
+19% +$2.46M 0.37% 65
2023
Q2 		$14.3M Buy
421,615
+111
+0% +$3.74K 0.34% 68
2023
Q1 		$15.2M Hold
421,504
– – 0.36% 68
2022
Q4 		$18.8M Sell
421,504
-100
-0% -$3.57K 0.45% 60
2022
Q3 		$11.9M Buy
421,604
+86,127
+26% +$2.64M 0.31% 72
2022
Q2 		$9.04M Buy
335,477
+238,160
+245% +$6.92M 0.26% 81
2022
Q1 		$3.31M Buy
+97,317
New +$3.11M 0.08% 116

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rock Springs Capital Management's CLDX Position: Q2 2026 in Review

Rock Springs Capital Management increased its Celldex Therapeutics (CLDX) stake by 7.5% in Q2 2026, buying an estimated $1.58M and bringing the position to 699,146 shares worth $26M. The position accounts for 1.27% of the portfolio, ranked #20.

Rock Springs Capital Management first reported a position in CLDX in Q1 2022 and has held it in 18 quarters since. The position peaked at $57.6M in Q1 2024. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Rock Springs Capital Management held 699,146 shares of Celldex Therapeutics worth $26M as of Q2 2026.
  • Rock Springs Capital Management bought 48,876 Celldex Therapeutics shares in Q2 2026, an estimated $1.58M.
  • Celldex Therapeutics made up 1.27% of Rock Springs Capital Management's portfolio in Q2 2026, its #20 holding.
  • Rock Springs Capital Management first reported a position in Celldex Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Rock Springs Capital Management's Celldex Therapeutics position peaked at $57.6M in Q1 2024.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.